The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.
April 24th 2024
A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
MRSA Decolonization: Balancing Intervention with Potential Resistance
February 17th 2016Many patients contract MRSA during their ICU stays, and it can progress to serious infections and chronic colonization with a high likelihood of recurrent infection. The leading intervention is primary precautions, including contact precautions and active surveillance testing.
Game-changing Dermatology Treatment for Hidradenitis Suppurativa Patients
“Hidradenitis suppurativa (HS) is a nightmare, probably the most negatively life-impacting disease we see in all of dermatology. We finally have a therapy to address it, “ remarked Jeffrey Sobell, assistant professor of dermatology, Tufts University School of Medicine, Boston, MA, at the Skin Disease Education Foundation (SDEF) Hawaii Dermatology Seminar.
Q&A: Common Misconceptions About Psoriatic Arthritis
Psoriatic arthritis, a chronic skin condition that affects patients on physically and mentally – often impacts patients’ mobility in their daily lives. Healthcare professionals across all specialties have experience when dealing with these patients in different capacities.
Patients with Psoriatic Arthritis Treated with Biologics Have Higher Infection Rates
New analysis of data from longitudinal cohorts finds that psoriatic arthritis patients were more than 50% more likely than those with psoriasis but no arthritis to develop infection. It also provides further evidence that biologic medications are also a risk factor for infection.
MDs on Gun Violence: Ten Angry Answers
January 25th 2016More than 900 physicians who subscribe to MD Magazine’s email news took the time last week to answer a seven-question survey on whether physicians should play a role in curbing gun violence. Here are the ten most passionate responses, taken from both sides
New Indications for Psoriasis Drug Cosentyx Receive FDA Nod
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
Analysis: Skin Cancer Risks, Recurrence, Metastasis, and Death
Researchers reviewed all published data regarding the risk for recurrence, metastasis and disease specific death related to cutaneous squamous cell carcinoma (cSCC) and found that tumor depth and tumor diameter are important factors.